Dr. Mercury Yusheng Lin, MD

Dr. Lin practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Lin's NPI, 1619947397, was assigned on January 25, 2006. Dr. Lin graduated from New York Medical College in 2003. Dr. Lin holds California license A88435.

Dr. Lin's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Lin's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Lin is also affiliated with Hoag Hospital Newport Beach. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Lin to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Lin is board certified in pathology - anatomic/pathology - clinical by the American Board of Pathology. Dmand AI has Dr. Lin's licenses on file in 2 states: California and Washington.

CMS data shows 2,549 Medicare services from Dr. Lin across 7 procedure codes in 2024, for 167 Medicare patients. Medicare paid $60,764 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 167 Medicare patients who saw Dr. Lin in 2024. The largest group is under 65, with 55 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 41% are also on Medicaid. Their average risk score is 3.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 58, with 46% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Lin, published from 2015 to 2022. 2015 was the busiest year, with 2. The most frequent topics are Biopsy, Diabetic Nephropathies and Kidney Glomerulus. Dr. Lin has published most often in Clin Kidney J. Dr. Lin's most frequent co-authors are Charles E. Alpers, Michifumi Yamashita, MD, PhD and Audai Abedrabboh Alrwashdeh.

CMS Open Payments shows 4 general payments to Dr. Lin from 2 drug and device companies from 2017 to 2019. Food and beverage make up the largest share, 100% of the total. Alexion Pharmaceuticals, Inc. paid the most, $361.

Dr. Lin graduated from New York Medical College in 2003.

Dr. Lin is in network with 5 carriers, including United Healthcare, Blue Cross and Blue Shield of Kansas City and CMS Medicare. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.